Cinromide plus ASMs vs placebo plus ASMs
50% or greater reduction in seizure frequency · Lennox‐Gastaut syndrome, any age
It is very uncertain whether cinromide plus ASMs changes number of participants with ≥ 50% reduction in mean weekly seizures compared with placebo plus ASMs (very low certainty).
1 finding from 1 review
- RR 1.15 [0.47, 2.86]1 study · 56 participantsVery low